Dementia prevention and treatment are fast-growing areas of research. Though there is no cure, we are closer than ever to understanding how the disease develops and its risk factors.
The future of dementia prevention
Recent studies have found evidence that vaccines against shingles – a variant of chickenpox – and respiratory syncytial virus (RSV) – a common respiratory infection – reduce the risk of dementia by up to 29%1.
While the mechanism behind this is not certain, researchers believe it may relate to the presence of a particular adjuvant, AS011. Adjuvants help the body to produce a stronger immune response, enhancing the effect of the vaccine2. AS01 may work by stimulating cells of the immune system that could help protect the brain against some of the harmful processes of dementia1. This protection works in tandem with the benefits of preventing infections like shingles and RSV.
Further research is required to establish whether the vaccines work to prevent dementia or delay its onset, but the findings are very promising.
Improving treatments for Alzheimer’s
Without clinical trial volunteers, there would only be limited advances in medical treatments, and few medications would be approved for use. With your participation, you may be able to contribute to scientific research which may lead to expansion of the treatment options for people with Alzheimer’s disease.
MAC Clinical Research is conducting a new study for a potential Alzheimer’s treatment (not vaccine based). If eligible, you and your caregiver/study partner will each receive up to £1595 for your time and commitment, plus travel expenses or transport for clinic visits.
Find out more and register your or a loved one’s interest via our Alzheimer’s research webpage.
References
1 University of Oxford – How do vaccines reduce the risk of dementia?
2 Centre for Disease Control – Adjuvants and Vaccines | Vaccine Safety
